05:19 PM EDT, 05/20/2025 (MT Newswires) -- Genfit ( GNFT ) said late Tuesday it will receive a 26.5 million Euro ($29.9 million) milestone payment from Ipsen after Iqirvo's approval of pricing and reimbursement in Italy for Primary Biliary Cholangitis.

The payment milestone under the licensing and collaboration agreement with Ipsen will further support Genfit ( GNFT ) in advancing its pipeline for severe liver diseases, according to a statement.